887 related articles for article (PubMed ID: 9485192)
1. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.
Seliger B; Harders C; Lohmann S; Momburg F; Urlinger S; Tampé R; Huber C
Eur J Immunol; 1998 Jan; 28(1):122-33. PubMed ID: 9485192
[TBL] [Abstract][Full Text] [Related]
2. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP and MHC class I expression and their upregulation by IFN-gamma.
Seliger B; Dunn T; Schwenzer A; Casper J; Huber C; Schmoll HJ
Scand J Immunol; 1997 Dec; 46(6):625-32. PubMed ID: 9420627
[TBL] [Abstract][Full Text] [Related]
4. Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression.
Seliger B; Höhne A; Knuth A; Bernhard H; Ehring B; Tampé R; Huber C
Clin Cancer Res; 1996 Aug; 2(8):1427-33. PubMed ID: 9816317
[TBL] [Abstract][Full Text] [Related]
5. LMP-associated proteolytic activities and TAP-dependent peptide transport for class 1 MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12.
Rotem-Yehudar R; Groettrup M; Soza A; Kloetzel PM; Ehrlich R
J Exp Med; 1996 Feb; 183(2):499-514. PubMed ID: 8627162
[TBL] [Abstract][Full Text] [Related]
6. Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin.
Delp K; Momburg F; Hilmes C; Huber C; Seliger B
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S88-95. PubMed ID: 10933198
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression.
Seliger B; Hohne A; Knuth A; Bernhard H; Meyer T; Tampe R; Momburg F; Huber C
Cancer Res; 1996 Apr; 56(8):1756-60. PubMed ID: 8620489
[TBL] [Abstract][Full Text] [Related]
8. MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components.
Garcia-Lora A; Martinez M; Algarra I; Gaforio JJ; Garrido F
Int J Cancer; 2003 Sep; 106(4):521-527. PubMed ID: 12845647
[TBL] [Abstract][Full Text] [Related]
9. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.
Seliger B; Harders C; Wollscheid U; Staege MS; Reske-Kunz AB; Huber C
Exp Hematol; 1996 Sep; 24(11):1275-9. PubMed ID: 8862437
[TBL] [Abstract][Full Text] [Related]
10. Gene transfer of human interferon gamma complementary DNA into a renal cell carcinoma line enhances MHC-restricted cytotoxic T lymphocyte recognition but suppresses non-MHC-restricted effector cell activity.
Schendel DJ; Falk CS; Nössner E; Maget B; Kressenstein S; Urlinger S; Tampé R; Gansbacher B
Gene Ther; 2000 Jun; 7(11):950-9. PubMed ID: 10849555
[TBL] [Abstract][Full Text] [Related]
11. IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma.
Seliger B; Hammers S; Höhne A; Zeidler R; Knuth A; Gerharz CD; Huber C
Clin Cancer Res; 1997 Apr; 3(4):573-8. PubMed ID: 9815722
[TBL] [Abstract][Full Text] [Related]
12. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation.
Seliger B; Atkins D; Bock M; Ritz U; Ferrone S; Huber C; Störkel S
Clin Cancer Res; 2003 May; 9(5):1721-7. PubMed ID: 12738726
[TBL] [Abstract][Full Text] [Related]
13. Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: lessons from recurrent tumors.
Zheng P; Sarma S; Guo Y; Liu Y
Cancer Res; 1999 Jul; 59(14):3461-7. PubMed ID: 10416611
[TBL] [Abstract][Full Text] [Related]
14. In situ analysis of the antigen-processing machinery in acute myeloid leukaemic blasts by tissue microarray.
Hoves S; Aigner M; Pfeiffer C; Laumer M; Obermann EC; Mackensen A
Leukemia; 2009 May; 23(5):877-85. PubMed ID: 19148137
[TBL] [Abstract][Full Text] [Related]
15. Genes encoded in the major histocompatibility complex affecting the generation of peptides for TAP transport.
Cerundolo V; Kelly A; Elliott T; Trowsdale J; Townsend A
Eur J Immunol; 1995 Feb; 25(2):554-62. PubMed ID: 7875220
[TBL] [Abstract][Full Text] [Related]
16. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma.
Atkins D; Breuckmann A; Schmahl GE; Binner P; Ferrone S; Krummenauer F; Störkel S; Seliger B
Int J Cancer; 2004 Mar; 109(2):265-73. PubMed ID: 14750179
[TBL] [Abstract][Full Text] [Related]
17. Identification of human cancers deficient in antigen processing.
Restifo NP; Esquivel F; Kawakami Y; Yewdell JW; Mulé JJ; Rosenberg SA; Bennink JR
J Exp Med; 1993 Feb; 177(2):265-72. PubMed ID: 8426105
[TBL] [Abstract][Full Text] [Related]
18. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
[TBL] [Abstract][Full Text] [Related]
19. Rescue of MHC-1 antigen processing machinery by down-regulation in expression of IGF-1 in human glioblastoma cells.
Pan Y; Trojan J; Guo Y; Anthony DD
PLoS One; 2013; 8(3):e58428. PubMed ID: 23526983
[TBL] [Abstract][Full Text] [Related]
20. Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer.
Romero JM; Jiménez P; Cabrera T; Cózar JM; Pedrinaci S; Tallada M; Garrido F; Ruiz-Cabello F
Int J Cancer; 2005 Feb; 113(4):605-10. PubMed ID: 15455355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
